文献速递临床试验与 GCP流行病学与生物统计

招募失败与无效是临床试验中止最常见原因:荷兰全国性起始队列研究结果

Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands.
PubMed 文献 · J Clin Epidemiol · 2017-05-06

该研究追踪了2007年荷兰机构审查委员会审核的所有临床试验药物研究至2015年12月,通过荷兰主管机构数据库和主要研究者问卷获取数据,主要结局为试验中止原因。574项试验中102项(17.8%)中止,最常见原因为招募失败(33/574;5.7%)和仅疗效相关原因(30/574;5.2%)。在疗效相关中止的试验中,10/30(33.3%)的方案报告了数据监查委员会、停止规则和期中分析时点全部三个方面,20/30(66.7%)报告了至少一个方面。

要点

  • 574项临床试验药物研究中102项(17.8%)在计划结束前中止。
  • 最常见中止原因为招募失败(33/574;5.7%)和仅疗效相关原因(30/574;5.2%)。
  • 疗效相关中止的30项试验中,仅10项(33.3%)方案报告了数据监查委员会、停止规则和期中分析时点全部三个方面。

核心结论

  • 约五分之一的临床试验药物研究在计划结束前中止,招募失败和无效是最常见原因。
  • 作者认为试验的目标样本量应可行,期中分析应在试验方案中充分描述。

研究设计与样本

  • 全国性起始队列研究,纳入2007年荷兰机构审查委员会审核的所有临床试验药物研究,随访至2015年12月。
  • 数据通过荷兰主管机构(中央人体研究委员会[CCMO])数据库和主要研究者问卷获取。
  • 主要结局为试验中止原因,分别分析全因、招募失败和疗效相关(期中分析显示无效或优效)三类原因。

主要发现

  • 574项试验中102项(17.8%)中止。
  • 最常见中止原因为招募失败(33/574;5.7%)和仅疗效相关原因(30/574;5.2%)。
  • 疗效相关中止的30项试验中,10项(33.3%)方案报告了数据监查委员会、停止规则和期中分析时点全部三个方面,20项(66.7%)报告了至少一个方面。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of the study was to identify the reasons for discontinuation of clinical drug trials and to evaluate whether efficacy-related discontinuations were adequately planned in the trial protocol. STUDY DESIGN AND SETTING: All clinical drug trials in the Netherlands, reviewed by institutional review boards in 2007, were followed until December 2015. Data were obtained through the database of the Dutch competent authority (Central Committee on Research Involving Human Subjects [CCMO]) and a questionnaire to the principal investigators. Reasons for trial discontinuation were the primary outcome of the study. Three reasons for discontinuation were analyzed separately: all cause, recruitment failure, and efficacy related (when an interim analysis had demonstrated futility or superiority). Among the efficacy-related discontinuations, we examined whether the data monitoring committee, the stopping rule, and the moment of the interim analysis in the trial progress were specified in the trial protocol. RESULTS: Of the 574 trials, 102 (17.8%) were discontinued. The most common reasons were recruitment failure (33 of 574; 5.7%) and solely efficacy related (30 of 574; 5.2%). Of the efficacy-related discontinuations, 10 of 30 (33.3%) of the trial protocols reported all three aspects in the trial protocol, and 20 of 30 (66.7%) reported at least one aspect in the trial protocol. CONCLUSION: One out of five clinical drug trials is discontinued before the planned trial end, with recruitment failure and futility as the most common reasons. The target sample size of trials should be feasible, and interim analyses should be adequately described in trial protocols.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. van den Bogert CA, Souverein PC, Brekelmans CTM, et al. Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands. J Clin Epidemiol. 2017. PMID: 28487159. doi:10.1016/j.jclinepi.2017.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。